MDM2 and schwannoma: Another study found that the re-introduction of merlin into merlin-deficient schwannoma cells increased p53 levels and its activity and that the treatment of merlin-deficient schwannoma cells with an MDM2 antagonist (nutlin-3) reduced cell survival in vitro and tumor growth in vivo [41].